Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/21
bluebird bio Reports Second Quarter Financial Results and Provides Operational UpdateBusiness Wire • 08/09/21
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 08/04/21
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/28/21
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell TherapiesBusiness Wire • 07/28/21
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling DonorBusiness Wire • 07/21/21
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRACBenzinga • 07/09/21
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EUBusiness Wire • 07/09/21
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 VirtualBusiness Wire • 06/11/21